Report: Alexion taps financial advisers for potential Roche deal

Despite considerable skepticism among the analysts who track Roche's every move, the buzz about a potential multibillion-dollar bid for Alexion will not die. Bloomberg has now revived speculation about a potential acquisition, reporting that Alexion ($ALXN) has brought in Goldman Sachs to advise the company after Roche ($RHHBY) made an informal approach in recent days.

News of the overture and Alexion's response immediately triggered a fresh surge in Alexion's share price, which has swelled in recent weeks as rumors of a takeover bid circulated. Alexion's market cap is now about $23 billion, exactly half of what Roche paid for Genentech.

Roche is reportedly fixed on the notion that it can quickly build on Alexion's success in the rare-disease field. The biotech company turned Soliris--the world's most expensive drug--into a blockbuster. And there's more in Alexion's pipeline that could duplicate that record. The R&D work could also help jump-start the makeover of pRED, an R&D arm that has suffered repeated setbacks over the past two years as one blockbuster hopeful after the next failed in late-stage studies.

Roche's $46 billion Genentech buyout proved to be a real winner in the oncology field, advancing several pioneering therapies. Now its best second act could be in rare diseases--though the price in this heated M&A market remains a daunting obstacle.

Neither company would confirm nor deny Bloomberg's report, which only added more fuel to the fire. Earlier this week, in reporting second-quarter earnings, Roche CEO Severin Schwan answered questions about a potential Alexion deal with a pledge to continue looking for bolt-on deals. "It has always been our strategy to have internal and external innovation," he said.

- read the Bloomberg news

Special Reports: Soliris - Top 20 Orphan Drugs by 2018 | Leonard Bell - Top 20 Highest-Paid Biopharma CEOs

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.